Nextbiotix raises 7M€

Nextbiotix, a microbiome biotech company developing innovative Live Biotherapeutics using commensal bacteria as drugs to treat major inflammatory bowel diseases, announced that it has completed a €7m Series A financing round to bring its lead candidate into the clinic. The round was led by Auriga Partners, alongside with Sofimac Innovation, Cap Innov’Est, INRA, and Biocodex, an independent multinational pharmaceutical company.

More information inthe Press Release below.